Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer

被引:65
作者
Iwanaga, K
Sueoka, N
Sato, A
Sakuragi, T
Sakao, Y
Tominaga, M
Suzuki, T
Yoshida, Y
K-Tsuzuku, J
Yamamoto, T
Hayashi, S
Nagasawa, K
Sueoka, E [1 ]
机构
[1] Saga Med Sch, Dept Internal Med, Saga 8498501, Japan
[2] Saga Med Sch, Dept Thorac & Cardiovasc Surg, Saga 8498501, Japan
[3] Saga Med Sch, Dept Pathol, Saga 8498501, Japan
[4] Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan
关键词
Tob; tumor suppressor gene; lung cancer; bronchial dysplasia; ErbB-2;
D O I
10.1016/j.canlet.2003.08.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Tob is a member of the Tob/BTG family, a novel class of anti-proliferative proteins. To investigate the involvement of tob as a tumor suppressor gene in human lung cancer, we analyzed the expression of tob mRNA and protein in lung cancer tissue and adjacent normal lung tissue. Immunohistochemical analysis using anti-Tob antibody showed decreased expression of Tob in 72% (31/43) of lung cancer tissues. Furthermore, 95% (19/20) of squamous cell carcinoma patients showed an apparent decrease in Tob in cancer tissues, associated with smoking status. The phosphorylated form of Tob, an inactive form of Tob, was detected in 76% (16/21) of cancer tissues of adenocarcinoma patients, but not in normal alveolar epithelial cells. Either a decrease in Tob expression or an accumulation of phosphorylated Tob was observed from early clinical stages, even in bronchial dysplasia, a premalignant lesion of squamous cell carcinoma. The above findings suggest that the disruption of antiproliferative Tob plays a distinct part in the early stage of lung carcinogenesis. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:71 / 79
页数:9
相关论文
共 22 条
[1]
Brambilla E, 1999, CLIN CANCER RES, V5, P243
[2]
FONG KM, 1995, CANCER RES, V55, P4268
[3]
Arrest of G1-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription [J].
Guardavaccaro, D ;
Corrente, G ;
Covone, F ;
Micheli, L ;
D'Agnano, I ;
Starace, G ;
Caruso, M ;
Tirone, F .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (05) :1797-1815
[4]
Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases [J].
Ikematsu, N ;
Yoshida, Y ;
Kawamura-Tsuzuku, J ;
Ohsugi, M ;
Onda, M ;
Hirai, M ;
Fujimoto, J ;
Yamamoto, T .
ONCOGENE, 1999, 18 (52) :7432-7441
[5]
KAKIZOE T, 1999, CANC STAT JAPAN, P104
[6]
Kohno H, 1999, CANCER, V85, P341, DOI 10.1002/(SICI)1097-0142(19990115)85:2<341::AID-CNCR11>3.3.CO
[7]
2-J
[8]
Matsuda S, 1996, ONCOGENE, V12, P705
[9]
5' CPG ISLAND METHYLATION IS ASSOCIATED WITH TRANSCRIPTIONAL SILENCING OF THE TUMOR-SUPPRESSOR P16/CDKN2/MTS1 IN HUMAN CANCERS [J].
MERLO, A ;
HERMAN, JG ;
MAO, L ;
LEE, DJ ;
GABRIELSON, E ;
BURGER, PC ;
BAYLIN, SB ;
SIDRANSKY, D .
NATURE MEDICINE, 1995, 1 (07) :686-692
[10]
Miller Carl W., 1997, Leukemia (Basingstoke), V11, P370